The drug has been approved for treatment-naive patients who are ineligible for transplant.
European regulators have expanded the label on Johnson & Johnson’s multiple myeloma drug Velcade to cover mantle cell lymphoma.
Specifically, the European Commission has approved a variation to the terms of J&J unit Janssen’s marketing authorisation of Velcade (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for adults with previously-untreated MCL who are unsuitable for blood stem-cell transplantation. The drug is currently indicated in Europe for multiple myeloma, either as monotherapy or in combinations.
Thomas Stark, head of medical affairs at Janssen Europe, Middle East and Africa, noted that “we already offer Imbruvica (ibrutinib) as a second-line treatment in MCL and are pleased to be able to provide additional treatment options for this disease”. Velcade is already approved for MCL in the USA, marketed by Takeda’s Millennium unit.
Complete report on PharmacyTimes: http://bit.ly/16Kaawc
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen